AGEN Profile
Agenus Inc. is a clinical-stage immuno-oncology company dedicated to discovering and developing innovative immuno-oncology products both in the United States and internationally. Utilizing its Retrocyte Display, an advanced antibody expression platform, Agenus identifies fully human and humanized monoclonal antibodies. The company also develops cutting-edge display technologies and vaccine programs, including the Prophage vaccine candidate and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant that enhances immune response.
Agenus has an extensive pipeline of therapeutic candidates targeting various forms of cancer. Key products in development include Balstilimab, an anti-PD-1 antagonist in Phase II clinical trials for second-line cervical cancer, and AGEN1181, an anti-CTLA-4 monospecific antibody in Phase 1/2 trials. Other notable candidates include AGEN2373, an anti-CD137 antibody in Phase 1 trials; AGEN1423, a bi-functional anti-CD73/TGFß TRAP antibody; and AGEN1777, an anti-TIGIT bispecific antibody. The company's diverse portfolio also features INCAGN1876, INCAGN1949, INCAGN2390, and INCAGN2385, which target GITR, OX40, TIM-3, and LAG-3 respectively, as well as MK-4830 targeting ILT4, and AGENT 797, an iNKT cell therapy in Phase 1 trials for various cancers and viral ARDS.
Operating under several trademarks such as ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, Agenus collaborates with major industry players including Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Originally known as Antigenics Inc., the company rebranded to Agenus Inc. in January 2011. Established in 1994 and headquartered in Lexington, Massachusetts, Agenus continues to advance its mission of pioneering new treatments to harness the power of the immune system against cancer.
|
